Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
H.U. Group Holdings, Inc. (4544.T)
Tokyo, JP
Established in 1950 and headquartered in Tokyo, Japan, H.U. Group Holdings, Inc. (formerly Miraca Holdings Inc. until its rebranding in July 2020) provides an extensive array of laboratory testing products and services through its subsidiaries across Japan. The company delivers diagnostic testing and associated services to medical facilities, supports self-medication initiatives, and conducts testing for food, environmental samples, and cosmetic products. Additionally, it offers testing solutions tailored for corporate health insurance programs. The group is deeply involved in the research, development, manufacturing, and commercialization of in vitro diagnostic devices. Its product lineup features the LUMIPULSE, an automated chemiluminescent enzyme immunoassay system that supplies reagents for the detection of infectious diseases, various cancers, and lifestyle-related conditions to medical institutions and diagnostic centers. H.U. Group also produces the ESPRINE series of rapid diagnostic kits for ailments such as influenza, hepatitis B, and the novel coronavirus, alongside supplying essential ingredients for test drugs. Beyond diagnostics, the company offers crucial support services for hospital administration, including assistance during surgical and endoscope procedures, inspection and maintenance of medical equipment, and in-hospital logistics and transportation management. Furthermore, it addresses the elderly care market by renting and selling specialized equipment and supplies, and by providing in-home nursing care services.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.43% | +3.51% | +1.11% | -0.38% | -13.16% | -6.99% | +3.61% | +16.09% | -1.03% | -29.68% | +421.64% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | -1 |
| Sell | 1 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+1.8% Q1'26: -0.6% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+149.9% ★ Q1'26: +3,905.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+8.5% Q1'26: +14.6% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+1.9% Q1'26: +1.0% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+2.3% Q1'26: +1.5% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-1.1% ★ Q1'26: -2.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×2.80× Q1'26: 3.21× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 4 EPS Ana. |
Mar 2027 4 Rev. Ana. 4 EPS Ana. |
Mar 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
204.67B
est: 206.60B (-0.9%)
|
211.74B
est: 209.97B (+0.8%)
|
204.25B
est: 204.36B (-0.1%)
|
195.40B
est: 197.40B (-1.0%)
|
181.42B
est: 181.15B (+0.1%)
|
188.71B
est: 188.90B (-0.1%)
|
223.02B
est: 222.72B (+0.1%)
|
272.94B
est: 265.48B (+2.8%)
|
260.91B
est: 262.45B (-0.6%)
|
236.95B
est: 239.80B (-1.2%)
|
243.03B
est: 243.30B (-0.1%)
|
248.60B
245.53B – 252.62B
+2.2% YoY
|
259.71B
255.09B – 262.42B
+4.5% YoY
|
273.05B
269.25B – 277.21B
+5.1% YoY
|
| EBITDA |
40.16B
est: 28.14B (+42.7%)
|
19.20B
est: 28.59B (-32.9%)
|
18.04B
est: 27.83B (-35.2%)
|
2.89B
est: 26.88B (-89.3%)
|
21.27B
est: 24.67B (-13.8%)
|
17.67B
est: 25.73B (-31.3%)
|
33.63B
est: 30.33B (+10.9%)
|
56.34B
est: 36.15B (+55.8%)
|
42.97B
est: 35.74B (+20.2%)
|
13.65B
est: 30.55B (-55.3%)
|
24.55B
est: 31.00B (-20.8%)
|
31.67B
31.28B – 32.18B
+2.2% YoY
|
33.09B
32.50B – 33.43B
+4.5% YoY
|
34.79B
34.30B – 35.32B
+5.1% YoY
|
| EBIT |
24.92B
est: 13.32B (+87.1%)
|
4.21B
est: 13.54B (-68.9%)
|
4.92B
est: 13.18B (-62.6%)
|
-6.75B
est: 12.73B (-153.0%)
|
11.57B
est: 11.68B (-0.9%)
|
6.34B
est: 12.18B (-47.9%)
|
21.13B
est: 14.36B (+47.2%)
|
41.72B
est: 17.12B (+143.7%)
|
23.28B
est: 16.92B (+37.5%)
|
-7.22B
est: 11.83B (-161.1%)
|
3.81B
est: 12.00B (-68.3%)
|
12.26B
12.11B – 12.46B
+2.2% YoY
|
12.81B
12.58B – 12.94B
+4.5% YoY
|
13.46B
13.28B – 13.67B
+5.1% YoY
|
| Net Income |
16.00B
est: 15.60B (+2.5%)
|
-5.08B
est: -5.72B (+11.2%)
|
333.00M
est: 3.51B (-90.5%)
|
257.00M
est: 8.66B (-97.0%)
|
6.39B
est: 8.03B (-20.5%)
|
-516.00M
est: 2.08B (-124.8%)
|
17.47B
est: 17.48B (-0.1%)
|
29.60B
est: 28.52B (+3.8%)
|
15.68B
est: 19.08B (-17.8%)
|
-7.55B
est: -6.26B (-20.7%)
|
2.76B
est: 513.64M (+437.5%)
|
6.71B
5.93B – 7.00B
+1,206.8% YoY
|
6.44B
6.02B – 7.22B
-4.0% YoY
|
9.37B
8.02B – 11.01B
+45.4% YoY
|
| SGA |
40.05B
est: 43.39B (-7.7%)
|
41.88B
est: 44.09B (-5.0%)
|
40.60B
est: 42.92B (-5.4%)
|
45.08B
est: 41.45B (+8.8%)
|
38.90B
est: 38.04B (+2.3%)
|
39.42B
est: 39.67B (-0.6%)
|
42.09B
est: 46.77B (-10.0%)
|
51.18B
est: 55.75B (-8.2%)
|
51.57B
est: 55.11B (-6.4%)
|
50.05B
est: 50.88B (-1.6%)
|
48.08B
est: 51.63B (-6.9%)
|
52.75B
52.10B – 53.60B
+2.2% YoY
|
55.11B
54.13B – 55.68B
+4.5% YoY
|
57.94B
57.13B – 58.82B
+5.1% YoY
|
| EPS |
274.83
est: 274.63 (+0.1%)
|
-89.20
est: -100.67 (+11.4%)
|
5.84
est: 61.85 (-90.6%)
|
4.50
est: 152.38 (-97.0%)
|
111.94
est: 141.30 (-20.8%)
|
-9.06
est: 36.65 (-124.7%)
|
306.38
est: 307.63 (-0.4%)
|
519.55
est: 501.89 (+3.5%)
|
275.51
est: 334.57 (-17.7%)
|
-132.77
est: -110.08 (-20.6%)
|
48.59
est: 9.16 (+430.6%)
|
115.14
105.48 – 124.49
+1,157.3% YoY
|
121.16
107.11 – 128.39
+5.2% YoY
|
182.12
142.62 – 195.94
+50.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-01 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-15 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-14 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shigekazu Takeuchi | Chairman | 100M | male |
| Hisashi Yamakawa | Manager of IR/SR Department - Corporate Planning Division | — | — |
| Isao Tada | Division Head of Procurement Division | — | — |
| Kazuya Omi | Executive Officer | — | male |
| Makoto Matsumoto | Managing Executive Officer, LTS | — | male |
| Naoki Kitamura | Managing Executive Officer of Finance & Director | — | male |
| Tadashi Hasegawa | Executive Officer | — | male |
| Takayuki Yoshizumi | Executive Officer, Human Resources and General Affairs | — | — |
| Goki Ishikawa | President, Group CEO & Representative Executive Officer | — | male |
| Toshihiko Shimizu | Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4544.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
